Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis
| Autor: | Véronique Loustaud-Ratti, Armand Abergel, Nicolas Andant, A. Mallat, Marie Dodel, Isabelle Fouchard-Hubert, Stanislas Pol, Maud Reymond, Brigitte Chanteranne, Bruno Pereira, François Bailly, Dominique Larrey, Albert Tran, Didier Samuel, Frederic Faure, Vincent Di Martino, J. Gournay, Benjamin Buchard, Tarik Asselah, Géraldine Lamblin, Leon Muti, Camille Teilhet |
|---|---|
| Přispěvatelé: | Service d'Hépatologie Gastro-entérologie [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Unité de recherche Maladies Métaboliques et Micronutriments (U3M), Institut National de la Recherche Agronomique (INRA), Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut des Maladies de l’Appareil Digestif [CHU Nantes], Université de Limoges (UNILIM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Cyclopropanes Male medicine.medical_specialty Elbasvir Asia Genotype [SDV]Life Sciences [q-bio] Fixed-dose combination Hepacivirus Antiviral Agents Gastroenterology Therapy naive 03 medical and health sciences 0302 clinical medicine Fibrosis Quinoxalines Internal medicine Ribavirin medicine Clinical endpoint Humans ComputingMilieux_MISCELLANEOUS Aged Benzofurans Sulfonamides Hepatology business.industry Imidazoles Middle Aged medicine.disease Amides Hepatitis C 3. Good health Europe Grazoprevir 030220 oncology & carcinogenesis Drug Therapy Combination Female 030211 gastroenterology & hepatology Carbamates business Viral load |
| Zdroj: | Liver International Liver International, Wiley-Blackwell, 2020, 40 (8), pp.1853-1859. ⟨10.1111/liv.14502⟩ |
| ISSN: | 1478-3223 1478-3231 |
| Popis: | BACKGROUND Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing treatment duration can improve adherence, reduce drug exposure and cost. Accordingly, we evaluated the efficacy of 8 weeks fixed-dose combination of grazoprevir-elbasvir in treatment-naive patients, with non-severe fibrosis. METHODS HCV mono-infected and treatment naive patients with non-severe fibrosis (Fibroscan® |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text